Biochemical impact of dexmedetomidine on inflammatory and stress markers in gastric cancer surgery: A meta-analysis.
[BACKGROUND] Dexmedetomidine, an a2-adrenergic agonist, has been reported to modulate inflammatory responses and neuroendocrine stress in surgical settings.
- 연구 설계 meta-analysis
APA
Zhang X, Hu W, et al. (2026). Biochemical impact of dexmedetomidine on inflammatory and stress markers in gastric cancer surgery: A meta-analysis.. Journal of medical biochemistry, 44(9), 1879-1890. https://doi.org/10.5937/jomb0-60059
MLA
Zhang X, et al.. "Biochemical impact of dexmedetomidine on inflammatory and stress markers in gastric cancer surgery: A meta-analysis.." Journal of medical biochemistry, vol. 44, no. 9, 2026, pp. 1879-1890.
PMID
41799718
Abstract
[BACKGROUND] Dexmedetomidine, an a2-adrenergic agonist, has been reported to modulate inflammatory responses and neuroendocrine stress in surgical settings. This meta-analysis evaluated its effects on serum biochemical markers of inflammation and stress in patients undergoing gastric cancer surgery.
[METHODS] Literature was retrieved from PubMed, CNKI, Wanfang, and VIP databases. Studies comparing dexmedetomidine anesthesia with conventional regimens in gastric cancer surgery were included. RevMan 5.2 was used for meta-analysis. Outcome indicators included interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), cortisol, epinephrine, adrenocorticotropic hormone (ACTH), heart rate (HR), mean arterial pressure (MAP), and adverse events.
[RESULTS] Fifteen studies were analyzed. Compared with controls, dexmedetomidine significantly reduced serum levels of IL-6, TNF-a, cortisol, epinephrine, and ACTH (all P < 0.00001). It also decreased HR, MAP visual analog scale (VAS) scores, and incidence of adverse reactions.
[CONCLUSIONS] Dexmedetomidine anesthesia effectively reduces biochemical markers of inflammation and stress in gastric cancer surgery, suggesting its beneficial role in modulating perioperative biochemical responses.
[METHODS] Literature was retrieved from PubMed, CNKI, Wanfang, and VIP databases. Studies comparing dexmedetomidine anesthesia with conventional regimens in gastric cancer surgery were included. RevMan 5.2 was used for meta-analysis. Outcome indicators included interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), cortisol, epinephrine, adrenocorticotropic hormone (ACTH), heart rate (HR), mean arterial pressure (MAP), and adverse events.
[RESULTS] Fifteen studies were analyzed. Compared with controls, dexmedetomidine significantly reduced serum levels of IL-6, TNF-a, cortisol, epinephrine, and ACTH (all P < 0.00001). It also decreased HR, MAP visual analog scale (VAS) scores, and incidence of adverse reactions.
[CONCLUSIONS] Dexmedetomidine anesthesia effectively reduces biochemical markers of inflammation and stress in gastric cancer surgery, suggesting its beneficial role in modulating perioperative biochemical responses.
같은 제1저자의 인용 많은 논문 (5)
- Effects of varicocele and microsurgical varicocelectomy on the metabolites in semen.
- Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia.
- IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells.
- MASH and liver fibrosis: Clinical trials to watch.
- E3 ubiquitin ligase DTX3L promotes breast cancer progression by enhancing PKCα ubiquitination and inhibiting the p38 MAPK signaling pathway.